Incontinence & Female Urology & Neurourology(구연) (NP-002) 과민성방광 환자들에서 Mirabegron 단독요법 및 Mirabegron과 Imidafenacine 복합요법의 효능 전남대학교병원 비뇨의학과 송재익, 이호연, 김재현, 임도경, 김태희, 은성종, 오주용, 유성현, 김명수, 정호석, 유호송, 오경진, 김선옥, 정승일, 강택원, 권동득, 박광성 Objective: We investigated the effect of mirabegron (50mg) only and combination of mirabegron and imidafenacine on the patients with overactive bladder (OAB). Patients and Methods: From January 2016 to July 2017, 138 patients with OAB symptoms were retrospectively reviewed. The patients were treated with mirabegron alone (50 mg/day; group I, n=78) or with mirabegron combined with imidafenacine (0.1 mg BID; group II, n=60). After 12 weeks, the OABSS, IPSS and uroflowmetric values were compared between groups. Results: The total IPSS, the storage symptom score and the voiding symptom score, were remarkably improved from baseline score after 12 weeks of treatment in both groups (p<0.05). Meanwhile, the storage symptom score was significantly improved after the treatment in group II compared with group I (p=0.002). Maximal flow rate (Qmax) and voiding volume (VV) of uroflowmetric parameters were significantly improved in both group without statistically significant difference between two groups. Group I showed significant improvement in post-voiding residual urine but group II did not show statistical changes. The OABSS was numerically improved without statistically significance in both (group I, p=0.163 group II, p= 0.798). Conclusion: Mirabegron or combination therapy of mirabegron with iminafenacine, both regimen clinically improved the subjective symptoms and objective parameters in patients with OAB symptoms. Combination of mirabegron with iminafenacine would have an additive effect in relieving the storage symptoms for the patients with severe OAB symptoms. keywords : Mirabegron, Imidafenacine, OAB